Dataset Information

Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers.

ABSTRACT: UNLABELLED:Approximately half of the familial aggregation of breast cancer remains unexplained. A multiple-case breast cancer family exome-sequencing study identified three likely pathogenic mutations in RINT1 (NM_021930.4) not present in public sequencing databases: RINT1 c.343C>T (p.Q115X), c.1132_1134del (p.M378del), and c.1207G>T (p.D403Y). On the basis of this finding, a population-based case-control mutation-screening study was conducted that identified 29 carriers of rare (minor allele frequency < 0.5%), likely pathogenic variants: 23 in 1,313 early-onset breast cancer cases and six in 1,123 frequency-matched controls [OR, 3.24; 95% confidence interval (CI), 1.29-8.17; P = 0.013]. RINT1 mutation screening of probands from 798 multiple-case breast cancer families identified four additional carriers of rare genetic variants. Analysis of the incidence of first primary cancers in families of women carrying RINT1 mutations estimated that carriers were at increased risk of Lynch syndrome-spectrum cancers [standardized incidence ratio (SIR), 3.35; 95% CI, 1.7-6.0; P = 0.005], particularly for relatives diagnosed with cancer under the age of 60 years (SIR, 10.9; 95% CI, 4.7-21; P = 0.0003). SIGNIFICANCE:The work described in this study adds RINT1 to the growing list of genes in which rare sequence variants are associated with intermediate levels of breast cancer risk. Given that RINT1 is also associated with a spectrum of cancers with mismatch repair defects, these findings have clinical applications and raise interesting biological questions.

SUBMITTER: Park DJ

PROVIDER: S-EPMC4234633 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers.

Park Daniel J DJ Tao Kayoko K Le Calvez-Kelm Florence F Nguyen-Dumont Tu T Robinot Nivonirina N Hammet Fleur F Odefrey Fabrice F Tsimiklis Helen H Teo Zhi L ZL Thingholm Louise B LB Young Erin L EL Voegele Catherine C Lonie Andrew A Pope Bernard J BJ Roane Terrell C TC Bell Russell R Hu Hao H Shankaracharya Huff Chad D CD Ellis Jonathan J Li Jun J Makunin Igor V IV John Esther M EM Andrulis Irene L IL Terry Mary B MB Daly Mary M Buys Saundra S SS Snyder Carrie C Lynch Henry T HT Devilee Peter P Giles Graham G GG Hopper John L JL Feng Bing-Jian BJ Lesueur Fabienne F Tavtigian Sean V SV Southey Melissa C MC Goldgar David E DE

Cancer discovery 20140502 7

<h4>Unlabelled</h4>Approximately half of the familial aggregation of breast cancer remains unexplained. A multiple-case breast cancer family exome-sequencing study identified three likely pathogenic mutations in RINT1 (NM_021930.4) not present in public sequencing databases: RINT1 c.343C>T (p.Q115X), c.1132_1134del (p.M378del), and c.1207G>T (p.D403Y). On the basis of this finding, a population-based case-control mutation-screening study was conducted that identified 29 carriers of rare (minor a ...[more]

PMID: 25050558

Similar Datasets

Project description:Mismatch repair-deficient breast cancers may be identified in Lynch syndrome mutation carriers, and have clinicopathological features in common with mismatch repair-deficient colorectal and endometrial cancers such as tumour-infiltrating lymphocytes and poor differentiation. Mismatch repair-deficient colorectal cancers frequently show mucinous differentiation associated with upregulation of chromosome 11 mucins. The aim of this study was to compare the protein expression of these mucins in mismatch repair-deficient and -proficient breast cancers. Cases of breast cancer (n=100) were identified from families where (1) both breast and colon cancer co-occurred and (2) families met either modified Amsterdam criteria or had at least one early-onset (<50 years) colorectal cancer. Tumour sections were stained for the epithelial mucins, MUC2, MUC5AC, MUC5B and MUC6, and the homeobox protein CDX2, a regulator of MUC2 expression. In all, 16 mismatch repair-deficient Lynch syndrome breast cancers and 84 non-Lynch breast cancers were assessed for altered mucin expression. No significant difference in the expression of MUC2, MUC5AC or MUC6 was observed between the mismatch repair-deficient and mismatch repair-proficient breast cancers; however, there was a trend for mismatch repair-deficient tumours to express high levels of MUC5B less frequently (P=0.07, OR=0.2 (0.0-1.0)). Co-expression of two or more gel-forming mucins was common. Ectopic expression of CDX2 was associated with expression of MUC2 (P=0.035, OR=8.7 (1.3-58.4)). Mismatch repair-deficient breast cancers do not show differential expression of the mucins genes on chromosome 11 when compared with mismatch repair-proficient breast cancers, in contrast with mismatch repair-deficient colorectal and endometrial cancers, which frequently have increased mucin protein expression when compared with their mismatch repair-proficient counterparts. In addition, ectopic CDX2 expression is positively associated with de novo MUC2 expression.

Dataset Information

Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers.

Publications

Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets